nach oben

Erschienen in:

24.05.2018 | Original Article

Factors predicting intolerance to definitive conventional radiotherapy in geriatric patients

verfasst von: Chai Hong Rim, MD, Won Sup Yoon, MD PhD, Jung Ae Lee, MD PhD, Dae Sik Yang, MD PhD, Nam Kwon Lee, MD PhD, Young Je Park, MD PhD, Chul Yong Kim, MD PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Although radiotherapy can be administered with a relatively low therapeutic burden, many elderly patients do not complete radiotherapy. In order to predict intolerance during radiotherapy, this study retrospectively analyzed the frequency of and risk factors for radiotherapy interruption among geriatric patients.

Methods

From September 2009 to December 2016, 353 patients aged ≥70 years received definitive radiotherapy with a conventionally fractionated schedule. “Total interruption” included completion of ≤90% of a planned radiotherapy, temporary discontinuation, and treatment-related mortality within 2 months. “Early-phase incompletion” and “mid-phase incompletion” represented completion of ≤50 and ≤80% of a planned radiotherapy, respectively.

Results

The median age of patients was 74 years. Early- and mid-phase incompletions and total interruption occurred in 4.2, 9.3, and 19.3% of patients, respectively. Total interruption occurred frequently in cancers involving the thorax (27.4%), head and neck (23.1%), abdomen (20.0%), pelvis (17.4%), and breast/extremity (8.1%). The Eastern Cooperative Oncology Group (ECOG) performance score (P = 0.004 and 0.002), serum albumin level (P = 0.016 and 0.002), and the expected 5‑year survival (P = 0.033 and 0.034) were significant factors for mid-phase incompletion and total interruption. Age ≥ 75 years (P = 0.008), concurrent chemotherapy (P = 0.017), and the extent of radiation field (P = 0.027) were factors associated with total interruption.

Conclusion

Overall, 19.3% of the elderly patients showed treatment intolerance during conventional radiotherapy. Serum albumin level and ECOG performance score should be considered as surrogate markers for radiotherapy interruption prior to the decision regarding definite conventional radiotherapy.

Nur mit Berechtigung zugänglich

Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2095–2128. https://doi.org/10.1016/S0140-6736(12)61728-0 CrossRefPubMed

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E (2012) Cancer treatment and survivorship statistics, 2012. Ca Cancer J Clin 62(4):220–241. https://doi.org/10.3322/caac.21149 CrossRefPubMed

Deiner S, Westlake B, Dutton RP (2014) Patterns of surgical care and complications in elderly adults. J Am Geriatr Soc 62(5):829–835. https://doi.org/10.1111/jgs.12794 CrossRefPubMedPubMedCentral

Semrau R, Herzog SL, Vallbohmer D, Kocher M, Holscher A, Muller RP (2012) Radiotherapy in elderly patients with inoperable esophageal cancer. Is there a benefit? Strahlenther Onkol 188(3):226–232. https://doi.org/10.1007/s00066-011-0039-2 CrossRefPubMed

Semrau S, Zettl H, Hildebrandt G, Klautke G, Fietkau R (2014) Older patients with inoperable non-small cell lung cancer: long-term survival after concurrent chemoradiotherapy. Strahlenther Onkol 190(12):1125–1132. https://doi.org/10.1007/s00066-014-0710-5 CrossRefPubMed

Lee JA, Lee NK, Yoon WS, Yang DS, Kim CY, Lee SR, Seong HJ (2017) Treatment interruption during radiation therapy: experience at a single institution in the Republic of Korea. Asia Pac J Clin Oncol 13(5):e481–e488. https://doi.org/10.1111/ajco.12572 CrossRefPubMed

Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, Levine RM, Lubiner ET, Reyes P, Schreiber FJ 3rd, Balducci L (2012) Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-age patients (CRASH) score. Cancer 118(13):3377–3386. https://doi.org/10.1002/cncr.26646 CrossRefPubMed

Fagard K, Casaer J, Wolthuis A, Flamaing J, Milisen K, Lobelle JP, Wildiers H, Kenis C (2017) Value of geriatric screening and assessment in predicting postoperative complications in patients older than 70 years undergoing surgery for colorectal cancer. J Geriatr Oncol 8(5):320–327. https://doi.org/10.1016/j.jgo.2017.07.008 CrossRefPubMed

Gani F, Cerullo M, Amini N, Buettner S, Margonis GA, Sasaki K, Kim Y, Pawlik TM (2017) Frailty as a risk predictor of morbidity and mortality following liver surgery. J Gastrointest Surg 21(5):822–830. https://doi.org/10.1007/s11605-017-3373-6 CrossRefPubMed

10.

Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29(25):3457–3465. https://doi.org/10.1200/JCO.2011.34.7625 CrossRefPubMedPubMedCentral

11.

Kenig J, Richter P, Zychiewicz B, Olszewska U (2014) Vulnerable Elderly Survey 13 as a screening method for frailty in Polish elderly surgical patient—prospective study. Pol Przegl Chir 86(3):126–131. https://doi.org/10.2478/pjs-2014-0024 CrossRefPubMed

12.

Puts MT, Monette J, Girre V, Pepe C, Monette M, Assouline S, Panasci L, Basik M, Miller WH Jr., Batist G, Wolfson C, Bergman H (2011) Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. Crit Rev Oncol Hematol 78(2):138–149. https://doi.org/10.1016/j.critrevonc.2010.04.003 CrossRefPubMed

13.

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging mamnual, 7th edn. Lippincott Raven, Philadelphia

14.

Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M (2013) Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol 37(3):219–225. https://doi.org/10.1016/j.canep.2013.02.002 CrossRefPubMed

15.

Steele CB, Li J, Huang B, Weir HK (2017) Prostate cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. Cancer 123(Suppl 24):5160–5177. https://doi.org/10.1002/cncr.31026 CrossRefPubMed

16.

Putz F, Putz T, Goerig N, Knippen S, Gryc T, Eyupoglu I, Rossler K, Semrau S, Lettmaier S, Fietkau R (2016) Improved survival for elderly married glioblastoma patients: better treatment delivery, less toxicity, and fewer disease complications. Strahlenther Onkol 192(11):797–805. https://doi.org/10.1007/s00066-016-1046-0 CrossRefPubMed

17.

Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham BC, Goss GD, National Cancer Institute of Canada Clinical Trials G (2008) Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 26(1):54–59. https://doi.org/10.1200/JCO.2007.12.8322 CrossRefPubMed

18.

Hines RB, Chatla C, Bumpers HL, Waterbor JW, McGwin G Jr., Funkhouser E, Coffey CS, Posey J, Manne U (2009) Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer. J Clin Oncol 27(26):4339–4345. https://doi.org/10.1200/JCO.2009.22.4758 CrossRefPubMedPubMedCentral

19.

Tetsche MS, Dethlefsen C, Pedersen L, Sorensen HT, Norgaard M (2008) The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study. BMC Cancer 8:31. https://doi.org/10.1186/1471-2407-8-31 CrossRefPubMedPubMedCentral

20.

Adams P, Ghanem T, Stachler R, Hall F, Velanovich V, Rubinfeld I (2013) Frailty as a predictor of morbidity and mortality in inpatient head and neck surgery. JAMA Otolaryngol Head Neck Surg 139(8):783–789. https://doi.org/10.1001/jamaoto.2013.3969 CrossRefPubMed

21.

Extermann M (2000) Measuring comorbidity in older cancer patients. Eur J Cancer 36(4):453–471CrossRef

22.

Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291(20):2441–2447. https://doi.org/10.1001/jama.291.20.2441 CrossRefPubMed

23.

Bahig H, Fortin B, Alizadeh M, Lambert L, Filion E, Guertin L, Ayad T, Christopoulos A, Bissada E, Soulieres D, Gaba Idiamey F, Nguyen-Tan PF (2015) Predictive factors of survival and treatment tolerance in older patients treated with chemotherapy and radiotherapy for locally advanced head and neck cancer. Oral Oncol 51(5):521–528. https://doi.org/10.1016/j.oraloncology.2015.02.097 CrossRefPubMed

24.

Choi Y, Kim JH, Kim JW, Kim JW, Lee KW, Oh HK, Kim DW, Kang SB, Song C, Kim JS (2016) Preoperative chemoradiotherapy for elderly patients with locally advanced rectal cancer—a real-world outcome study. Jpn J Clin Oncol 46(12):1108–1117. https://doi.org/10.1093/jjco/hyw126 CrossRefPubMed

25.

Di Genesio Pagliuca M, Perotti C, Apicella G, Galla A, Guffi M, Paolini M, Donis L, Amisano V, Torrente S, Manfredda I, Krengli M (2016) Concurrent chemo-radiotherapy in elderly patients: tolerance and compliance in a series of 137 patients. Clin Transl Oncol 18(6):571–575. https://doi.org/10.1007/s12094-015-1403-y CrossRefPubMed

26.

Straube C, Scherb H, Gempt J, Bette S, Zimmer C, Schmidt-Graf F, Schlegel J, Meyer B, Combs SE (2017) Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience. Radiat Oncol 12(1):77. https://doi.org/10.1186/s13014-017-0809-9 CrossRefPubMedPubMedCentral

27.

Wang W, Hou X, Yan J, Shen J, Lian X, Sun S, Liu Z, Meng Q, Wang D, Zhao M, Qiu J, Hu K, Zhang F (2017) Outcome and toxicity of radical radiotherapy or concurrent chemoradiotherapy for elderly cervical cancer women. BMC Cancer 17(1):510. https://doi.org/10.1186/s12885-017-3503-2 CrossRefPubMedPubMedCentral

28.

Lai KM, Lin JT, Lu HJ, Liang CC, Chen MK (2017) Is definitive concurrent chemoradiotherapy effective for locally advanced head and neck cancer in the elderly aged ≥ 75 years: a single-institute, retrospective, cohort study. Asia Pac J Clin Oncol. https://doi.org/10.1111/ajco.12764 CrossRefPubMed

29.

Francois E, Azria D, Gourgou-Bourgade S, Jarlier M, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, Seitz JF, Conroy T, Juzyna B, Gerard JP (2014) Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy. Radiother Oncol 110(1):144–149. https://doi.org/10.1016/j.radonc.2013.10.019 CrossRefPubMed

30.

Takemoto S, Nakamura Y, Fukuda M, Senju H, Gyotoku H, Taniguchi H, Shimada M, Ikeda T, Yamaguchi H, Nakatomi K, Hayashi N, Soda H, Mukae H (2017) Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer. Thorac Cancer. https://doi.org/10.1111/1759-7714.12483 CrossRefPubMedPubMedCentral

31.

Pollom EL, Chin AL, Lee NY, Tsai CJ (2017) Patterns of care in adjuvant therapy for resected oral cavity squamous cell cancer in elderly patients. Int J Radiat Oncol Biol Phys 98(4):758–766. https://doi.org/10.1016/j.ijrobp.2017.01.224 CrossRefPubMed

32.

Kunkler IH, Audisio R, Belkacemi Y, Betz M, Gore E, Hoffe S, Kirova Y, Koper P, Lagrange JL, Markouizou A, Pfeffer R, Villa S, Force SRT (2014) Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Ann Oncol 25(11):2134–2146. https://doi.org/10.1093/annonc/mdu104 CrossRefPubMed

33.

McMillan MT, Ojerholm E, Verma V, Higgins KA, Singhal S, Predina JD, Berman AT, Grover S, Robinson CG, Simone CB 2nd (2017) Radiation treatment time and overall survival in locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 98(5):1142–1152. https://doi.org/10.1016/j.ijrobp.2017.04.004 CrossRefPubMed

Titel: Factors predicting intolerance to definitive conventional radiotherapy in geriatric patients
verfasst von: Chai Hong Rim, MD
Won Sup Yoon, MD PhD
Jung Ae Lee, MD PhD
Dae Sik Yang, MD PhD
Nam Kwon Lee, MD PhD
Young Je Park, MD PhD
Chul Yong Kim, MD PhD
Publikationsdatum: 24.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 10/2018
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1318-y

Neu im Fachgebiet Onkologie

10.04.2024 | PSA-Screening | Nachrichten

Springer Medizin

Factors predicting intolerance to definitive conventional radiotherapy in geriatric patients

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2018

Prof. Dr. Luther W. Brady verstorben

Complementary medicine in radiation oncology

Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math

Prognostic factors in stereotactic body radiotherapy of lung metastases

Stereotactic radiotherapy for choroidal melanomas by means of HybridArc™

Die Radiotherapie des Pleuramesothelioms – Klinische Praxisleitlinie der American Society of Clinical Oncology

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie